A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)

Phase 1 Completed 37 enrolled Merck Sharp & Dohme LLC

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a two-part study to test the safety, tolerability, and immune response for V934/V935 vaccine using a new prime-boost regimen in participants with selected solid tumors.

Timeline

Start: 2008-08
Primary completion: 2011-04
Completion: 2011-04

Publications

Aurisicchio L, Fridman A, Mauro D, Sheloditna R, Chiappori A, Bagchi A, Ciliberto G. Safety, tolerability and immunogenicity of V934/V935 hTERT vaccination in cancer patients with selected solid tumors: a phase I study. J Transl Med. 2020 Jan 30;18(1):39. doi: 10.1186/s12967-020-02228-9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	V934-EP	Vaccine	0.25 mg	Other
Subject	V934-EP	Vaccine	2.5 mg	Other
Subject	V935	Vaccine	5e+08 vg	Intramuscular
Subject	V935	Vaccine	5e+10 vg	Intramuscular

A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)

Summary

Timeline

Publications

Drugs

Indications